FindTrial
Sign In

Effects of aprepitant (Emend ®) on the concentration of fentanyl in blood

Effects of aprepitant (Emend ®) on the pharmacokinetics of fentanyl

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2013-002144-82-NL
Enrollment
Unknown
Registered
2013-08-08
Start date
2013-12-13
Completion date
Unknown
Last updated
2014-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer patients using a stable dose of a fentanyl patch as treatment for their continous pain MedDRA version: 16.0 Level: PT Classification code 10058019 Term: Cancer pain System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: durogesic Product Name: Durogesic Product Code: PA 748/2/1-5 Pharmaceutical Form: Transdermal patch Trade Name: Emend Product Name: emend Pharmaceutical Form: Tablet

Sponsors

None listed

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: age > = 18 stable use of fentanyl patch written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 14 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: using fentanyl as rescue medication intolerance for aprepitant

Design outcomes

Primary

MeasureTime frame
Main Objective: To determine the influence of administration of Emend on the pharmacokinetics of fentanyl.;Secondary Objective: not applicable;Primary end point(s): AUC, clearance;Timepoint(s) of evaluation of this end point: 2 years—

Secondary

MeasureTime frame
Secondary end point(s): not applicable;Timepoint(s) of evaluation of this end point: not applicable—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026